Mitoxantron und Immunglobuline

T. Henze

doi:10.1055/s-0038-1629964

Nervenheilkunde, Table of Contents

Nervenheilkunde 2005; 24(04): 287-293
DOI: 10.1055/s-0038-1629964

Geist & Gehirn

Schattauer GmbH

Mitoxantron und Immunglobuline

Indikationen, Wirksamkeit, VerträglichkeitMitoxantrone and immunoglobulins – indications, effectiveness, side effects

Authors

T. Henze

¹Klinik am Regenbogen, Fachklinik für Neurologische Rehabilitation, Nittenau (Ärztlicher Direktor: Prof. Dr. med. Thomas Henze)

Abstract

Zusammenfassung

Mitoxantron ist derzeit die wichtigste Substanz in der Eskalationstherapie der schubförmigen oder sekundär progredienten MS. Es führt sowohl zu einer Schubreduktion als auch zu einer Verlangsamung der klinischen und der radiologischen Progression. Die Substanz ist in der Regel gut verträglich. Auf Grund des Risikos einer Kardiomyopathie sollte jedoch eine Gesamtmenge von 140 mg/m² KOF nicht überschritten werden. Auch auf das sehr geringe Risiko einer späteren akuten Leukämie müssen die Patienten hingewiesen werden.

Intravenöse Immunglobuline (IVIg) sind bislang vor allem bei schubförmiger MS sowie bei schwangeren MS-Patientinnen mit schubförmigem Verlauf und dem Risiko eines postpartalen Schubes untersucht worden. Die Ergebnisse legen einen positiven Effekt auf die Schubreduktion sehr nahe, so dass IVIg als Reservemedikation innerhalb der Basistherapie bewertet werden. Zur Behandlung der sekundär progredienten MS sowie zur Verstärkung einer Remyelinisierung sind sie offenbar jedoch nicht geeignet. Auch IVIg werden in der Regel gut vertragen. Problematisch ist ihr Off-label-Status, so dass eine Kostenübernahme durch Krankenkassen oft nur schwer zu erreichen ist.

Summary

Mitoxantrone is nowadays the most important drug within escalation therapy of relapsing-remitting (RR-MS) and secondary progressive (SP-MS) multiple sclerosis. It may reduce the frequency of relapses and decelerate progression of clinical symptoms as well as of radiologic findings, e.g. whole lesion load and number of Gadolinium-enhancing lesions. Mitoxantrone is usually well tolerated. Nevertheless due to the risk of cardiomyopathy not more than 140 mg/m² should be administered during life. Moreover, there is a very small risk that leukaemia may develop as a sequel of mitoxantrone treatment.

Intravenous immunoglobulins (IVIg) have been investigated especially in RR-MS and in pregnant women with MS. The results demonstrate a reduction of the frequency of relapses and therefore IVIg may be used in RR-MS in cases when beta-interferon or glatirameracetate are not tolerated well. According to published data, IVIg do not play a role in the treatment of secondary progressive MS or to enhance remyelination. They are usually well tolerated, too. Because of their off label status IVIg are reimbursed by health insurances in only rare cases.

Schlüsselwörter

Multiple Sklerose - Therapie - Mitoxantron - Immunglobuline

Keywords

Multiple sclerosis - treatment - mitoxantrone - immunoglobulins

Full Text

References

Literatur
1 Achiron A, Rotstein Z, Noy S. et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-8.
2 Achiron A, Gabbay U, Gilad R. et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402.
3 Achiron A, Kishner I, Dolev M. et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-7.
4 Achiron A, Kishner I, Sarova-Pinhas I. et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. Arch Neurol 2004; 51: 1515-20.
5 Avasarala JR, Cross AH, Clifford DB. et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003; 9: 59-62.
6 Cattaneo C, Almici C, Borlenghi E. et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003; 17: 985-6.
7 Cohen B, Mikol DD. Mitoxantrone treatment of multiple sclerosis. Safety considerations. Neurology 2004; 63 (Suppl. 06) S28-S32.
8 Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11 (Suppl. 01) 54-8.
9 Edan G, Miller D, Clanet M. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-8.
10 Edan G, Morrissey SP, Hartung H-P. Use of mitoxantrone to treat multiple sclerosis. In: Cohen JA, Rudick RA. Multiple Sclerosis Therapeutics. 2nd edition. London & New York: Dunitz; 2003: 403-26.
11 Edan G, Brochet B, Clanet M. et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 2004; 62 (Suppl. 05) A493.
12 Fazekas F, Deisenhammer F, Strasser-Fuchs S. et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing- remitting multiple sclerosis. Lancet 1997; 349: 589-93.
13 Ghalie RG, Edan G, Laurent M. et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-13.
14 Ghalie RG, Mauch E, Edan G. et al. A study of therapy- related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-5.
15 Gold R, Hartung H-P. Aktueller Therapieüberblick und zukünftige Therapiestrategien der Multiplen Sklerose. Nervenheilkunde 2003; 22 (Suppl. 01) S16-S24.
16 Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients (Abstract). Neurology 1990; 40 (Suppl. 01) 261.
17 Goodkin DE. Therapy-related leukaemia in mitoxantrone treated patients. Mult Scler 2003; 9: 426.
18 Hartung HP, Gonsette R, König N. et al. Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
19 Hund E. Immunglobuline in der Neurologie. Bremen- London-Boston: Uni-Med; 2002
20 Hommes OR, Sorensen PS, Fazekas F. et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149-56.
21 Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS : clinical and MRI assessment. Eur J Neurol 2002; 9: 565-72.
22 Lipshultz SE, Rifai N, Dalton VM. et al. The effect of dexrazoxane on myocardial injury in doxorubicin- treated children with acute lymphoblastic leucemia. N Engl J Med 2004; 351: 145-53.
23 Millefiorini E, Gasperini C, Pozzilli C. et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-9.
24 Mogenet I, Simiand-Erdociain E, Canone J-M, Pris J. Acute myelogenous leucemia following mitoxantrone treatment for multiple sclerosis. Ann Pharmacother 2003; 37: 747-8.
25 Multiple Sklerose Therapie Konsensus Gruppe. Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 1999; 70: 371-86.
26 Noseworthy JH, O’Brien PC, Weinshenker BG. et al. IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebocontrolled trial. Neurology 2000; 55: 1135-43.
27 Noseworthy JH, O’Brien PC, Petterson TM. et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-22.
28 Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukaemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004; 18: 1561-2.
29 Rizvi SA, Zwibel H, Fox EJ. Mitoxantrone for multiple sclerosis in clinical practice. Neurology 2004; 63 (Suppl. 06) S25-S27.
30 Saccardi R, Tyndall A, Coghlan G. et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune disease, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplantation 2004; 34: 877-81.
31 Soelberg-Sörensen P, Haas J, Sellebjerg F. et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004; 63: 2028-33.
32 Sörensen PS, Wanscher B, Jensen CV. et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81.
33 Sörensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002; 9: 557-63.
34 Stangel M, Boegner F, Klatt CH. et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiat 2000; 68: 89-92.
35 Stangel M, Gold R. Einsatz von i.v. Immunglobulinen in der Neurologie. Evidenzbasierter Konsens. Nervenarzt 2004; 75: 801-16.
36 Visser LH, Beekman R, Tijssen CC. et al. A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10: 89-91.
37 Voltz R, Starck M, Zingler V. et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004; 10: 472-4.
38 Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004; 135: 49-55.